NCT03675737 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT03675737
Title	Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
Recruitment	Completed
Gender	both
Phase	Phase III
Variant Requirements	No
Sponsors	Merck Sharp & Dohme LLC
Indications	gastroesophageal junction adenocarcinoma gastric adenocarcinoma
Therapies	Capecitabine + Oxaliplatin Capecitabine + Oxaliplatin + Pembrolizumab Cisplatin + Fluorouracil + Pembrolizumab Cisplatin + Fluorouracil
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| POL \| NZL \| ITA \| ISR \| IRL \| HUN \| GBR \| FRA \| ESP \| DNK \| DEU \| CZE \| CHE \| CAN \| BRA \| AUS \| ARG

No variant requirements are available.